Basisstatistiken
| LEI | 529900QLMOA3D8VSCN33 |
| CIK | 1544227 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tempest Therapeutics, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 2, 2026 |
COMMON STOCK PURCHASE WARRANT TEMPEST THERAPEUTICS, INC. Warrant Shares: Issue Date: May 29, 2026 EX-10.2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV |
|
| June 2, 2026 |
EX-10.1 Exhibit 10.1 TEMPEST THERAPEUTICS, INC. May 28, 2026 Holder of Common Stock Purchase Warrants Issued in November 2025 Re: Inducement Offer to Exercise Common Stock Purchase Warrants Issued in November 2025 Dear Holder: Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive new warran |
|
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 2, 2026 |
EX-10.3 Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV |
|
| May 29, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Temp |
|
| May 14, 2026 |
Exhibit 99.1 Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Busine |
|
| May 14, 2026 |
Exhibit 10.4 May 12, 2026 Tempest Therapeutics, Inc. Attn: Nicholas Maestas, Chief Financial Officer and Head of Corporate Strategy 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 Factor Bioscience Inc. Attn: Matthew Angel, Ph.D., Chief Executive Officer 1035 Cambridge Street, Suite 17B Cambridge, MA 02141 Re: Amended and Restated Master Services Agreement (the “Agreement”) entered into on |
|
| May 14, 2026 |
FACTOR BIOSCIENCE INC. TEMPEST THERAPEUTICS, INC. Exhibit 10.3 November 19, 2025 Tempest Therapeutics, Inc. 2000 Sierra Point Parkway Suite 400 Brisbane, CA 94005 Attention: Stephen Brady Re: Funding Commitment Ladies and Gentlemen: Reference is made to that certain Asset Purchase Agreement (the “Purchase Agreement”) entered into as of the date hereof by and among Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), Erigen LLC, a D |
|
| May 6, 2026 |
® Developing Advanced Therapies for Cancer Patients EX-99.2 Exhibit 99.2 ® Developing Advanced Therapies for Cancer Patients Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) concerning Tempest Therapeutics, Inc. (“Tempest Therapeutics”). Thes |
|
| May 6, 2026 |
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting EX-99.1 Exhibit 99.1 Tempest Presents Clinical Update at ISCT 2026 Annual Meeting • 100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1) • Favorable safety profile with no Grade >3 CRS or ICANS in REDEEM-1 trial evaluating TPST-2003 in relapsed/refractor |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 10, 2026 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-294740 PROSPECTUS 8,268,495 Shares Common Stock This prospectus relates to the offer and resale from time to time of up to an aggregate 8,268,495 shares of our common stock, par value $0.001 per share (the “Shares”), by the selling stockholders named herein, together with any additional selling stockholders listed in a p |
|
| April 10, 2026 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-294843 PROSPECTUS 2,777,781 Shares Common Stock This prospectus relates to the offer and resale from time to time of up to an aggregate 2,777,781 shares of our common stock, par value $0.001 per share (the “Shares”) consisting of (i) 462,964 shares of our common stock, (ii) 925,927 shares of our common stock issuable upo |
|
| April 8, 2026 |
TEMPEST THERAPEUTICS, INC. 2000 Sierra Point Parkway, Suite 400 Brisbane, California CORRESP TEMPEST THERAPEUTICS, INC. 2000 Sierra Point Parkway, Suite 400 Brisbane, California April 8, 2026 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Alan Campbell Re: Tempest Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-294843) Request for Acceleration of Effective Date Mr. Campbell: |
|
| April 7, 2026 |
April 7, 2026 Matthew Angel Chief Executive Officer Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 Re: Tempest Therapeutics, Inc. Registration Statement on Form S-3 Filed April 2, 2026 File No. 333-294843 Dear Matthew Angel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regardin |
|
| April 2, 2026 |
Calculation of Filing Fee Tables S-3 Tempest Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| April 2, 2026 |
As filed with the Securities and Exchange Commission on April 1, 2026 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 1, 2026 Registration No. |
|
| April 1, 2026 |
April 1, 2026 Matthew Angel Chief Executive Officer Tempest Therapeutics, Inc. 200 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 Re: Tempest Therapeutics, Inc. Registration Statement on Form S-3 Filed March 30, 2026 File No. 333-294740 Dear Matthew Angel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regardin |
|
| April 1, 2026 |
TEMPEST THERAPEUTICS, INC. 2000 Sierra Point Parkway, Suite 400 Brisbane, California CORRESP TEMPEST THERAPEUTICS, INC. 2000 Sierra Point Parkway, Suite 400 Brisbane, California April 1, 2026 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Chris Edwards Re: Tempest Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-294740) Request for Acceleration of Effective Date Mr. Edwards: I |
|
| March 31, 2026 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2026 S-8 POS As filed with the U.S. Securities and Exchange Commission on March 31, 2026 Registration No. 333-294732 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempest Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State or other |
|
| March 30, 2026 |
Exhibit 99.1 Tempest Reports Year End 2025 Financial Results and Provides Business Update Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Brisbane, |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35890 Tempest Therapeutics, Inc. |
|
| March 30, 2026 |
AMENDMENT NO. 1 TO TEMPEST THERAPEUTICS, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN Exhibit 10.12 AMENDMENT NO. 1 TO TEMPEST THERAPEUTICS, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN In accordance with Section 2(b)(vii) of Tempest Therapeutics, Inc.’s (the “Company”) Amended and Restated 2023 Equity Incentive Plan (the “Plan”), the Plan is hereby amended as follows, subject to approval of the Company’s shareholders: 1. Section 3(a) of the Plan is hereby deleted and repla |
|
| March 30, 2026 |
Tempest Therapeutics, Inc. 2000 Shoreline Court, Suite 400 Brisbane, CA 94005 Exhibit 10.28 Tempest Therapeutics, Inc. 2000 Shoreline Court, Suite 400 Brisbane, CA 94005 November 19, 2025 Matthew Angel, Ph.D. VIA EMAIL Re: Executive Employment Agreement Dear Matthew: Tempest Therapeutics, Inc. (“Tempest” or the “Company”) is pleased to offer you employment on the terms set forth in this letter agreement (the “Agreement”). This offer of employment is conditioned upon the clo |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 30, 2026 |
Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 Exhibit 10.29 Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 February 3, 2026 Nicholas Maestas [address on file] RE: Executive Employment Agreement Dear Nic: This employment agreement (this “Agreement”) sets forth the terms and conditions of your employment as the Chief Financial Officer and Head of Corporate Strategy of Tempest Therapeutics, Inc. (“Temp |
|
| March 30, 2026 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Tempest Therapeutics, Inc. (the “Company,” or “we,” “us,” and “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (a) our common stock and (b) Series A junior participating preferred purchase rights (“Series |
|
| March 30, 2026 |
Exhibit 10.26 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT TEMPEST THERAPEUTICS, INC. TREATS AS PRIVATE AND CONFIDENTIAL AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT THIS AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of this 19 |
|
| March 30, 2026 |
As filed with the U.S. Securities and Exchange Commission on March 30, 2026 S-8 As filed with the U.S. Securities and Exchange Commission on March 30, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempest Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State or other jurisdiction of Incorporation or organiz |
|
| March 30, 2026 |
Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT TEMPEST THERAPEUTICS, INC. TREATS AS PRIVATE AND CONFIDENTIAL EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of this 18th day of July 2025 (t |
|
| March 30, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Tempest Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.001 par value per share, 2023 Equity Incentive Plan, together with the associated Series |
|
| March 30, 2026 |
Calculation of Filing Fee Tables S-3 Tempest Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| March 30, 2026 |
Exhibit 10.27 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT TEMPEST THERAPEUTICS, INC. TREATS AS PRIVATE AND CONFIDENTIAL AMENDED AND RESTATED MASTER SERVICES AGREEMENT THIS AMENDED AND RESTATED MASTER SERVICE AGREEMENT (this “Agreement”) is entered into as of this 19th day of November, 2 |
|
| March 30, 2026 |
As filed with the Securities and Exchange Commission on March 30, 2026 S-3 As filed with the Securities and Exchange Commission on March 30, 2026 Registration No. |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2026 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissi |
|
| March 23, 2026 |
EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| March 23, 2026 |
EX-10.2 Exhibit 10.2 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 20, 2026, by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursua |
|
| March 23, 2026 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 20, 2026, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| March 23, 2026 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 25, 2026 |
EX-99.1 Exhibit 99.1 Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 • 100% complete response (CR) rate among all six efficacy evaluable patients • Favorable safety profile with no Grade >3 CRS or ICANS • Prior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, inclu |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2026 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commis |
|
| February 6, 2026 |
EX-4.1 Exhibit 4.1 WARRANT AGREEMENT Dated as of February 3, 2026 between TEMPEST THERAPEUTICS, INC. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY N.A. as Warrant Agent Warrants for Shares of Common Stock of Tempest Therapeutics, Inc. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Rules of Construction 5 ARTICLE II F |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2026 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commis |
|
| January 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2026 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commiss |
|
| December 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35890 Tempest Therapeutics, Inc. |
|
| December 31, 2025 |
TABLE OF CONTENTS United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| December 9, 2025 |
Calculation of Filing Fee Tables S-1 Tempest Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| December 9, 2025 |
As filed with the Securities and Exchange Commission on December 9, 2025 S-1 Table of Contents As filed with the Securities and Exchange Commission on December 9, 2025 Registration No. |
|
| December 2, 2025 |
TABLE OF CONTENTS United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| November 26, 2025 |
EX-99.1 Exhibit 99.1 Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules November 25, 2025 $4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants Brisbane, CA, November 25, 2025 – T |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 24, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commi |
|
| November 26, 2025 |
EX-4.1 Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 24, 2025, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| November 26, 2025 |
EX-4.2 Exhibit 4.2 PREFUNDED COMMON STOCK PURCHASE WARRANT TEMPEST THERAPEUTICS, INC. Warrant Shares: Issue Date: November 26, 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| November 26, 2025 |
EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| November 25, 2025 |
487,000 Shares of Common Stock Prefunded Warrants to Purchase up to 685,414 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-280918 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 27, 2025) 487,000 Shares of Common Stock Prefunded Warrants to Purchase up to 685,414 Shares of Common Stock We are offering to a certain investor 487,000 shares of our common stock, par value $0.001 per share, or the common stock, and prefunded warrants to purcha |
|
| November 19, 2025 |
EX-10.2 Exhibit 10.2 LOCK-UP AGREEMENT November 19, 2025 Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, California To whom it may concern: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) contemporaneously entered into an Asset Purchase Agreement with Tempest Therapeutics, Inc., a Delaware corporation (“Purchaser”), dated as of the date firs |
|
| November 19, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation |
|
| November 19, 2025 |
EX-10.1 Exhibit 10.1 ASSET PURCHASE AGREEMENT by and between Erigen LLC, Factor Bioscience Inc. and Tempest Therapeutics, Inc. dated as of November 19, 2025 TABLE OF CONTENTS Page 1. DEFINITIONS 2 1.1 Defined Terms 2 1.2 Construction 17 2. PURCHASE AND SALE 18 2.1 Purchase and Sale of Assets 18 2.2 Excluded Assets 19 2.3 Assumed Liabilities 20 2.4 Excluded Liabilities 20 2.5 Consents an |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2025 |
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update Brisbane, CA, November 5, 2025 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30, 2025 and provided a corpora |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2025 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 |
|
| August 11, 2025 |
Form of Success Bonus Agreement Exhibit 10.6 Tempest Therapeutics, Inc. Success Bonus Agreement This Success Bonus Agreement (this “Agreement”) is entered into by Tempest Therapeutics, Inc. (the “Company”) and [NAME] (“Participant” or “you”), as of [], 2025. 1. Purpose. The purpose of this Agreement is to provide a cash bonus as an incentive for Participant to continue to provide services to the Company through the consummation |
|
| August 11, 2025 |
Exhibit 10.7 August 8, 2025 Justin Trojanowski Re: Tempest Employment Terms Dear Justin, You are currently employed by Tempest Therapeutics, Inc. ("Tempest" or the "Company") pursuant to the terms of the offer letter you entered into with the Company on May 19, 2022 (the “Offer Letter”). The terms and conditions set forth in this amended offer letter (this “Amended Offer Letter”) shall become effe |
|
| August 11, 2025 |
Exhibit 10.4 June 13, 2025 Sam Whiting, M.D., Ph.D. Re: Separation Agreement Dear Sam: This letter sets forth the substance of the separation agreement (the “Agreement”) that Tempest Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment termination date will be effective as of June 5, 2025 (the “Separation Date”). You understand |
|
| August 11, 2025 |
Exhibit 10.2 FORM OF CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into effective as of [ ], 2025 (the “Effective Date”) by and between Tempest Therapeutics, Inc., a Delaware corporation having its principal place of business located at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005 (“Company”), and [ ], an individual with a principal address set forth below (“C |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Tempe |
|
| August 11, 2025 |
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update • Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China • Granted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients with HCC • Presented new amezalpat mechanism-o |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 11, 2025 |
Exhibit 10.3 June 13, 2025 Stephen R. Brady Re: Separation Agreement Dear Steve: This letter sets forth the substance of the separation agreement (the “Agreement”) that Tempest Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment termination date will be June 5, 2025 (the “Separation Date”). You understand and agree that you are |
|
| August 11, 2025 |
Exhibit 10.5 June 13, 2025 Nicholas Maestas Re: Separation Agreement Dear Nic: This letter sets forth the substance of the separation agreement (the “Agreement”) that Tempest Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment termination date will be effective as of June 5, 2025 (the “Separation Date”). You understand and agre |
|
| June 12, 2025 |
405,000 Shares of Common Stock Prefunded Warrants to Purchase up to 334,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280918 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 27, 2025) 405,000 Shares of Common Stock Prefunded Warrants to Purchase up to 334,000 Shares of Common Stock We are offering to certain investors 405,000 shares of our common stock, par value $0.001 per share (the “Common Stock”) and prefunded warrants to purchase up to 334,000 shares of |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| June 12, 2025 |
Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT TEMPEST THERAPEUTICS, INC. Warrant Shares: Issue Date: June 12, 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| June 12, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June , 2025, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2025 |
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports First Quarter 2025 Financial Results and Provides Business Update • Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting • Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP) • Received FDA “Study May Proceed” letter for Phase 2 t |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Temp |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| April 30, 2025 |
Employment Agreement, dated January 12, 2022, by and between the Company and Stephen Brady Exhibit 10.11 TEMPEST THERAPEUTICS, INC. 7000 Shoreline Court, Suite 275 South San Francisco, California 94080 January 12, 2022 Via Email Only [email protected] Mr. Stephen R. Brady Chief Executive Officer RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Steve: On behalf of Tempest Therapeutics, Inc. (“Tempest”, or the “Company”), it is my pleasure to confirm the terms and conditions of your continued e |
|
| April 30, 2025 |
Exhibit 10.12 TEMPEST THERAPEUTICS, INC. 7000 Shoreline Court, Suite 275 South San Francisco, California 94080 January 12, 2022 Via Email Only [email protected] Sam Whiting, M.D., Ph.D. RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Sam: On behalf of Tempest Therapeutics, Inc. (“Tempest”, or the “Company”), it is my pleasure to confirm the terms and conditions of your continued employment as Tempest |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissi |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 8, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| April 9, 2025 |
Exhibit 99.1 Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value • Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in place • Awarded both Orphan Drug & Fast Track designations for amezal |
|
| April 7, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF TEMPEST THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Tempest Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation L |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2025 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| March 27, 2025 |
Tempest Therapeutics, Inc. Insider Trading Policy Exhibit 19.1 Tempest Therapeutics, Inc. Insider Trading Policy (Adopted March 25, 2025) Introduction During the course of your relationship with Tempest Therapeutics, Inc. (“Tempest”), you may receive material information that is not yet publicly available (“material nonpublic information”) about Tempest or other publicly traded companies. Material nonpublic information may give you, or someone yo |
|
| March 27, 2025 |
Exhibit 10.33 Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 January 1, 2025 Nicholas Maestas RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Nic: On behalf of Tempest Therapeutics, Inc. (“Tempest”, or the “Company”), it is my pleasure to confirm the terms and conditions of your continued employment as Tempest’s Chief Financial Officer and Head of Corporate Stra |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35890 Tempest Therapeutics, Inc. |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 27, 2025 |
Form of Tempest Therapeutics, Inc. Warrant to Purchase Stock Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| March 27, 2025 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Tempest Therapeutics, Inc. (the “Company,” or “we,” “us,” and “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (a) our common stock and (b) Series A junior participating preferred purchase rights (“Series |
|
| March 27, 2025 |
Exhibit 10.32 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (a) not material and (b) is the type that the registrant treats as private or confidential Master Clinical Supply Agreement This MASTER CLINICAL SUPPLY AGREEMENT (“Agreement”), effective as of the date of last signature on the signature page below (“Effective D |
|
| March 27, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tempest Therapeutics, Inc. |
|
| March 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 27, 2025 S-8 As filed with the U.S. Securities and Exchange Commission on March 27, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempest Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State or other jurisdiction of Incorporation or organiz |
|
| March 27, 2025 |
Tempest Reports Year End 2024 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Year End 2024 Financial Results and Provides Business Update • Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial • Received FDA “Study May Proceed” letter |
|
| February 6, 2025 |
Up to $14,500,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-280918 PROSPECTUS SUPPLEMENT (to Prospectus dated January 27, 2025) Up to $14,500,000 Common Stock We have entered into an Open Market Sale AgreementSM, dated June 20, 2024, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the offer and sale of shares of our common stock, par value $0.001 per share, f |
|
| January 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tempest Therapeutics, Inc. |
|
| January 24, 2025 |
As filed with the Securities and Exchange Commission on January 24, 2025 S-3/A As filed with the Securities and Exchange Commission on January 24, 2025 Registration No. |
|
| January 24, 2025 |
TEMPEST THERAPEUTICS, INC. 2000 Sierra Point Parkway, Suite 400 Brisbane, California, 94005 (415) 798-8589 January 24, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Gary Guttenberg RE: Tempest Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-280918 Acceleration Request Requested Date |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2024 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commis |
|
| December 6, 2024 |
EX-4.1 Exhibit 4.1 AMENDMENT NO. 2 TO RIGHTS AGREEMENT This AMENDMENT NO. 2 TO RIGHTS AGREEMENT, dated as of December 5, 2024 (this “Amendment”), is made and entered into by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as Rights Agent (the “Rights Agent”). Except as otherwise provided her |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 |
|
| November 12, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| November 12, 2024 |
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC - Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial - Rece |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| October 10, 2024 |
EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT This AMENDMENT NO. 1 TO RIGHTS AGREEMENT, dated as of October 9, 2024 (this “Amendment”), is made and entered into by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as Rights Agent (the “Rights Agent”). Except as otherwise provided here |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 7, 2024 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commiss |
|
| October 10, 2024 |
8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State of other jurisdiction of incorporation or organization) (I.R.S. Employer I.D. |
|
| October 10, 2024 |
Tempest Extends Limited Duration Stockholder Rights Plan EX-99.1 Exhibit 99.1 Tempest Extends Limited Duration Stockholder Rights Plan BRISBANE, Calif., October 10, 2024 —Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or the “Company”), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the “Board”) has adopted an amendment to its |
|
| August 12, 2024 |
TPST / Tempest Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d879964dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities |
|
| August 8, 2024 |
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update - Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC)” study demonstrating: • Survival benefit maintained across key subpopulations • a six-month improvement over control arm in median survival • a strong 0.65 hazard ratio, maintained si |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Tempe |
|
| July 23, 2024 |
July 23, 2024 Stephen Brady Chief Executive Officer Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, California, 94005 Re: Tempest Therapeutics, Inc. Registration Statement on Form S-3 Filed July 19, 2024 File No. 333-280918 Dear Stephen Brady: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 |
|
| July 19, 2024 |
Exhibit 4.4 TEMPEST THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 S |
|
| July 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tempest Therapeutics, Inc. |
|
| July 19, 2024 |
S-3 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 20, 2024 |
Up to $205,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-257990 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated July 23, 2021) Up to $205,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, dated June 20, 2024, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the offer and sale of shares of our common stock, par value $0.001 pe |
|
| June 20, 2024 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM June 20, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common |
|
| June 20, 2024 |
EX-99.1 Exhibit 99.1 Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm • 21 months median OS in amezalpat arm vs. 15 in control arm • 50% (20/40) of patients on amezalpat arm remain in survival follow up • 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier • Earl |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2024 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| May 13, 2024 |
TPST / Tempest Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87978U108 (CUSIP Number) Ver |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Temp |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP - Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting - Published positive data from the Phase 1 Trial of TPST-1120 in patients with advanced solid tumors in the Jo |
|
| April 23, 2024 |
2023 Annual Report www.TempestTX.comUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35890 Tempest Therap |
|
| April 23, 2024 |
DEF 14A Table of Contents United States Securities and Exchange Commission Washington, D. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 19, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Tempest Therapeutics, Inc. (the “Company,” or “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following descriptions of our capital stock, provisions of our restated c |
|
| March 19, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97.1 Tempest Therapeutics, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Po |
|
| March 19, 2024 |
Tempest Reports Year End 2023 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Year End 2023 Financial Results and Provides Business Update - Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of care - Reported new biomarker data in two important subpopulations, PD-L1 negative and b-catenin mutant patients, consistent with MoA of TPST-1120 - |
|
| March 19, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 19, 2024 |
Exhibit 10.26 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of November 3, 2023 (the “Second Amendment Da |
|
| March 19, 2024 |
As filed with the U.S. Securities and Exchange Commission on March 19, 2024 As filed with the U.S. Securities and Exchange Commission on March 19, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempest Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State or other jurisdiction of Incorporation or organizatio |
|
| March 19, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Tempest Therapeutics, Inc. Table 1 — Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.001 par value per share, 2023 Equity Incentive Plan Rule 457(c) and (h) |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35890 Tempest Therapeutics, Inc. |
|
| February 14, 2024 |
TPST / Tempest Therapeutics, Inc. / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
TPST / Tempest Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 tpst13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Tempest Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87978U108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 9, 2024 |
TPST / Tempest Therapeutics, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 TEMPEST THERAPEUTICS INC COMMON STOCK Cusip #87978U108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87978U108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 431,932 Item 6: 0 Item 7: 431,932 Item 8: 0 Item 9 |
|
| February 8, 2024 |
TPST / Tempest Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d768185dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities |
|
| November 17, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 Tempest Therapeutics, Inc. |
|
| November 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2023 S-8 As filed with the U.S. Securities and Exchange Commission on November 17, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempest Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State or other jurisdiction of Incorporation or organiz |
|
| November 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2023 S-8 POS As filed with the U.S. Securities and Exchange Commission on November 17, 2023 Registration No. 333-265718 Registration No. 333-264943 Registration No. 333-255261 Registration No. 333-249993 Registration No. 333-235515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-265718 Post-Effective Amendment No. 1 |
|
| November 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2023 S-8 POS As filed with the U.S. Securities and Exchange Commission on November 17, 2023 Registration No. 333-265718 Registration No. 333-264943 Registration No. 333-255261 Registration No. 333-249993 Registration No. 333-235515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-265718 Post-Effective Amendment No. 1 |
|
| November 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2023 S-8 POS As filed with the U.S. Securities and Exchange Commission on November 17, 2023 Registration No. 333-265718 Registration No. 333-264943 Registration No. 333-255261 Registration No. 333-249993 Registration No. 333-235515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-265718 Post-Effective Amendment No. 1 |
|
| November 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2023 S-8 POS As filed with the U.S. Securities and Exchange Commission on November 17, 2023 Registration No. 333-265718 Registration No. 333-264943 Registration No. 333-255261 Registration No. 333-249993 Registration No. 333-235515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-265718 Post-Effective Amendment No. 1 |
|
| November 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2023 S-8 POS As filed with the U.S. Securities and Exchange Commission on November 17, 2023 Registration No. 333-265718 Registration No. 333-264943 Registration No. 333-255261 Registration No. 333-249993 Registration No. 333-235515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-265718 Post-Effective Amendment No. 1 |
|
| November 9, 2023 |
TPST / Tempest Therapeutics Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d582597dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 |
|
| November 8, 2023 |
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update - TPST-1120 demonstrates superiority compared to standard of care across multiple study endpoints in randomized first-line HCC study - New capital strengthens balance sheet and extends cash runway into 2025 Brisbane, CA, November 8, 2023 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncol |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 8, 2023 |
Exhibit 10.1 Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, CA 94005 September 15, 2023 Via Email Only [Redacted] Tom Dubensky, Ph.D. RE: SEPARATION AND CONSULTING AGREEMENT Dear Tom: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Tempest Therapeutics, Inc. (the “Company”) is offering to you to aid in your employmen |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 12, 2023 |
TEMPEST THERAPEUTICS, INC. Up to $100,000,000 Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-257990 AMENDMENT NO. 1 DATED OCTOBER 12, 2023 (To Prospectus Supplement dated July 23, 2021 To Prospectus dated July 23, 2021) TEMPEST THERAPEUTICS, INC. Up to $100,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated April 14, 2022 (the “Prospectus Supplement”) and t |
|
| October 11, 2023 |
EX-99.1 Exhibit 99.1 Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study • New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezolizumab + bevacizumab in a global Phase 1b/2 study • 30% confirmed ORR achieved in TPST-1120 arm |
|
| October 11, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF TEMPEST THERAPEUTICS, INC. The undersigned, Stephen Brady, does hereby certify: 1. That he is duly elected and acting Chief Executive Officer of Tempest Therapeutics, Inc., a Delaware corporation (the “Corporation”). 2. That pursuant to the authority conferred upo |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Tempest Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commis |
|
| October 11, 2023 |
Tempest Adopts Limited Duration Stockholder Rights Plan EX-99.2 Exhibit 99.2 Tempest Adopts Limited Duration Stockholder Rights Plan BRISBANE, Calif., October 11, 2023 —Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights pla |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State of other incorporation or organization) (I.R.S. Employer I.D. No.) 2000 Sierra Point Par |
|
| October 11, 2023 |
EX-4.1 Exhibit 4.1 RIGHTS AGREEMENT October 10, 2023 TABLE OF CONTENTS Page SECTION 1. CERTAIN DEFINITIONS 1 SECTION 2. APPOINTMENT OF RIGHTS AGENT 8 SECTION 3. ISSUANCE OF RIGHTS 8 SECTION 4. FORM OF RIGHT CERTIFICATES 11 SECTION 5. COUNTERSIGNATURE AND REGISTRATION 12 SECTION 6. TRANSFER, SPLIT UP, COMBINATION AND EXCHANGE OF RIGHT CERTIFICATES; MUTILATED, DESTROYED, LOST OR STOLEN RIGHT CERTIFI |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2023 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 10, 2023 |
Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan. Exhibit 10.1 TEMPEST THERAPEUTICS, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN Approved by the Board of Directors: April 28, 2023 (the “Adoption Date”) Approved by the Stockholders: June 15, 2023 1. GENERAL. (a) Successor to and Continuation of the 2019 Plan. The Plan is intended as the successor to and continuation of the Tempest Therapeutics, Inc., Amended and Restated 2019 Equity Incen |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 10, 2023 |
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, August 10, 2023 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate up |
|
| August 10, 2023 |
Tempest Therapeutics, Inc. 2023 Inducement Plan Exhibit 10.3 TEMPEST THERAPEUTICS, INC. 2023 INDUCEMENT PLAN Adopted by the Board of Directors: June 21, 2023 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Tempe |
|
| August 10, 2023 |
Form of Option Grant Package under the 2023 Inducement Plan Exhibit 10.4 Tempest Therapeutics, Inc. Inducement Grant Outside of Amended and Restated 2019 Equity Incentive Plan Tempest Therapeutics, Inc. (the “Company”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below, outside of, but subject to the terms of, the Company’s Amended and Restated 2019 Equity Incentive Plan, as may be amende |
|
| August 10, 2023 |
Form of Stock Option Grant Notice under Amended and Restated 2023 Equity Incentive Plan. Exhibit 10.2 TEMPEST THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN) Tempest Therapeutics, Inc. (the “Company”), pursuant to its Amended and Restated 2023 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2023 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Temp |
|
| May 10, 2023 |
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports First Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, May 10, 2023 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023 and provided a corporate updat |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 1, 2023 |
DEF 14A Table of Contents United States Securities and Exchange Commission Washington, D. |
|
| May 1, 2023 |
DEFA14A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 1, 2023 |
2022 Annual Report www.TempestTX.commal UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35890 Tempest Th |
|
| April 28, 2023 |
EX-99.1 Exhibit 99.1 Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma • Positive randomized data with TPST-1120 combined with atezolizumab + bevacizumab compared head-to-head with atezolizumab + bevacizumab • The addition of TPST-1120 resulted in a clinically-meaningful improvement in both confirmed and |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2023 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissi |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Tempest Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissi |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K mal UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35890 Tempest Therapeutics, Inc. |
|
| March 22, 2023 |
Exhibit 10.24 THE TOWERS AT SIERRA POINT LEASE This Lease (the " XE "Lease" Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the " XE "Summary" Summary"), below, is made by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation (" XE "Landlord" Landlord"), and TEMPEST THERAPEUTICS, INC., a Delaware corporation (" XE "Tenant" Tenant"). SUMMARY |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Tempest Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35890 45-1472564 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 22, 2023 |
Tempest Reports Year End 2022 Financial Results and Provides Business Update Exhibit 99.1 Tempest Reports Year End 2022 Financial Results and Provides Business Update • Positive monotherapy and combination therapy data from Phase 1 trial of first clinical program, TPST-1120, announced in an oral presentation at ASCO 2022 • TPST-1120 randomized combination study in first-line HCC patients with partner Roche is fully enrolled, with initial data expected in the first half of |
|
| February 14, 2023 |
TPST / Tempest Therapeutics, Inc. / Rock Springs Capital Management LP Passive Investment SC 13G/A 1 rocksprings-tpst123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87978U108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2023 |
TPST / Tempest Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Tempest Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87978U108 (CUSIP Number) April 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 23, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commi |
|
| December 29, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of December 23, 2022 (the ?First Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (in its individual capacity, ?Oxford?; an |
|
| November 8, 2022 |
Written Agreement & Consent of Warrant Holders and Tempest Therapeutics, Inc. EX-10.1 2 ex101-writtenagreementcons.htm EX-10.1 Exhibit 10.1 WRITTEN AGREEMENT & CONSENT OF WARRANT HOLDERS AND TEMPEST THERAPEUTICS, INC. This Warrant Amendment Agreement (this “Agreement”), by and among Tempest Therapeutics, Inc., a Delaware corporation (the “Company”) and the undersigned holders (the “Holders”), as the sole and original holders of the Pre-Funded Common Stock Purchase Warrants |
|
| November 8, 2022 |
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update South San Francisco, CA, November 8, 2022 – Tempest Therapeutics, Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Tempest Therapeuti |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Comm |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Tempest Therapeutics, I |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commiss |
|
| August 15, 2022 |
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update South San Francisco, CA, August 15, 2022 ? Tempest Therapeutics, Inc. |
|
| August 15, 2022 |
Agreement for Termination of Lease and Voluntary Surrender of Premises AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Termination of Lease and Voluntary Surrender of Premises (this ?Agreement?) is made and entered into as of May 12, 2022, by and between ARE-SAN FRANCISCO NO. |
|
| June 21, 2022 |
As filed with the U.S. Securities and Exchange Commission on June 21, 2022 As filed with the U.S. Securities and Exchange Commission on June 21, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempest Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State or other jurisdiction of Incorporation or organization) ( |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissio |
|
| June 21, 2022 |
Amended and Restated 2019 Employee Stock Purchase Plan Exhibit 10.2 TEMPEST THERAPEUTICS, INC. AMENDED AND RESTATED 2019 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: APRIL 22, 2022 APPROVED BY THE STOCKHOLDERS: JUNE 17, 2022 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common |
|
| June 21, 2022 |
EX-FILING FEES 5 d307046dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 Tempest Therapeutics, Inc. Table 1 — Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $ |
|
| June 21, 2022 |
Amended and Restated 2019 Equity Incentive Plan Exhibit 10.1 TEMPEST THERAPEUTICS, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN AS AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: APRIL 22, 2022 APPROVED BY THE STOCKHOLDERS: JUNE 17, 2022 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Millendo Therapeutics, Inc. 2012 Stock Plan and the Ovascience, Inc. 2012 St |
|
| June 9, 2022 |
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance Exhibit 99.1 Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance ? TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpected ? RECIST responses observed with TPST-1120 combined with anti-PD1 therapy in patients who previously progressed on anti-PD1/PDL1 therapy ? Po |
|
| June 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commission |
|
| May 27, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-264989 PROSPECTUS 6,355,932 Shares Common Stock This prospectus relates to the proposed resale from time to time of up to 6,355,932 shares of our common stock, par value $0.001 per share, (the ?Resale Shares?), of which 3,149,912 shares are issued and outstanding and 3,206,020 shares (the ?Warrant Shares?) are issuab |
|
| May 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commission |
|
| May 26, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 26, 2022 |
Exhibit 99.1 Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting ? RECIST responses observed in IO-refractory patients and in IO-resistant indications ? 30% ORR in patients treated at the two highest TPST-1120 doses in combination with nivolumab (3/10); 20% ORR in all evaluable combination patients (3/15) ? 53% DCR |
|
| May 24, 2022 |
TEMPEST THERAPEUTICS, INC. 7000 Shoreline Court, Suite 275 South San Francisco, CA 94080 TEMPEST THERAPEUTICS, INC. 7000 Shoreline Court, Suite 275 South San Francisco, CA 94080 May 24, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Gary Guttenberg RE: Tempest Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-264989 Acceleration Request Requested Date: Friday, May 27, 2022 |
|
| May 18, 2022 |
United States securities and exchange commission logo May 18, 2022 Stephen Brady Chief Executive Officer Tempest Therapeutics, Inc. |
|
| May 16, 2022 |
Power of Attorney (see signature page to this registration statement) Table of Contents As filed with the Securities and Exchange Commission on May 16, 2022 Registration No. |
|
| May 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tempest Therapeutics, Inc. |
|
| May 13, 2022 |
Tempest Therapeutics, Inc. 7000 Shoreline Court, Suite 275 South San Francisco, California 94080 January 12, 2022 Via Email Only [email protected] Sam Whiting, M.D., Ph.D. RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Sam: On behalf of Tempest Therapeutics, Inc. (?Tempest?, or the ?Company?), it is my pleasure to confirm the terms and conditions of your continued employment as Tempest?s Chief Medic |
|
| May 13, 2022 |
EX-FILING FEES 5 d312473dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 Tempest Therapeutics, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $ |
|
| May 13, 2022 |
Tempest Therapeutics, Inc. 7000 Shoreline Court, Suite 275 South San Francisco, California 94080 January 12, 2022 Via Email Only [email protected] Nicholas M. Maestas RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Nic: On behalf of Tempest Therapeutics, Inc. (?Tempest?, or the ?Company?), it is my pleasure to confirm the terms and conditions of your continued employment as Tempest?s vice president, |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Tempest Therapeutics, |
|
| May 13, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 13, 2022 As filed with the U.S. Securities and Exchange Commission on May 13, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tempest Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 45-1472564 (State or other jurisdiction of Incorporation or organization) (I |
|
| May 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2022 |
Tempest Therapeutics, Inc. 7000 Shoreline Court, Suite 275 South San Francisco, California 94080 January 12, 2022 Via Email Only [email protected] Tom Dubensky, Ph.D. RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Tom: On behalf of Tempest Therapeutics, Inc. (?Tempest?, or the ?Company?), it is my pleasure to confirm the terms and conditions of your continued employment as Tempest?s President, repo |
|
| May 13, 2022 |
Executive Employment Agreement, dated January 12, 2022, by and between the Company and Stephen Brady Tempest Therapeutics, Inc. 7000 Shoreline Court, Suite 275 South San Francisco, California 94080 January 12, 2022 Via Email Only [email protected] Mr. Stephen R. Brady Chief Executive Officer RE: EXECUTIVE EMPLOYMENT AGREEMENT Dear Steve: On behalf of Tempest Therapeutics, Inc. (?Tempest?, or the ?Company?), it is my pleasure to confirm the terms and conditions of your continued employment as T |
|
| May 13, 2022 |
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights Exhibit 99.1 Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights ?Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCO ?Presented positive preclinical data for TPST-1495 at AACR ?Presented positive preclinical data with proprietary small molecule TREX1 inhibitors at AACR South San Francisco, CA, May 13, 2022 ? Tempest |
|
| May 9, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 9, 2022 |
TPST / Tempest Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87978U108 (CUSIP Number) Versant Ventu |
|
| May 9, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| May 9, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 2, 2022 |
Tempest Announces Private Placement Financing of $15 Million Exhibit 99.1 Tempest Announces Private Placement Financing of $15 Million South San Francisco, Calif., April 27, 2022 (GLOBE NEWSWIRE) ? Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing novel therapeutics that combine both targeted and immune-mediated mechanisms, today announced a $15 million private investment in public equity (PIPE) financing from the sale |
|
| May 2, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 2, 2022 |
Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting Exhibit 99.2 Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting ? Oral presentation for TPST-1120 completed Phase 1 trial results ? Poster presentation for TPST-1495 trial in progress South San Francisco, CA, April 27, 2022 ? Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapeutics that combine both targeted and immu |
|
| May 2, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of April 26, 2022, by and among Tempest Therapeutics, Inc., a Delaware corporation (the ?Company?), and the purchasers set forth on Schedule 1 hereto (each, a ?Purchaser?, and collectively, the ?Purchasers?), and shall become effective as of the Closing (as defined in the Purchase Agreement, |
|
| May 2, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of April 26, 2022, by and among Tempest Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). In the event that there is only a single Purcha |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2022 TEMPEST THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 45-1472564 (State or other jurisdiction of incorporation) (Commissi |
|
| May 2, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 2, 2022 |
DEF 14A 1 d342375ddef14a.htm DEF 14A Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 22, 2022 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 14, 2022 |
TEMPEST THERAPEUTICS, INC. Up to $6,600,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-257990 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated July 23, 2021 To Prospectus dated July 23, 2021) TEMPEST THERAPEUTICS, INC. Up to $6,600,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated July 23, 2021, filed with the Securities and Exchange Commission as a part of our regist |
|
| April 1, 2022 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Tempest Therapeutics, Inc. (the ?Company,? or ?we,? ?us,? and ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following descriptions of our capital stock, provisions of our restated c |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| April 1, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Tempest Therapeutics, Inc. Name of Subsidiary Jurisdiction of Organization TempestTx, Inc. Delaware, United States Millendo Therapeutics US, Inc. Delaware, United States |
